HDAC9 and ovarian carcinoma: Presently, there are three HDAC inhibitors available for the clinical treatment of ovarian cancer; there are many targeted drugs for acetylation in preclinical trials, and more targeted drugs for histone acetylation are waiting to be discovered (Marsh et al., 2014).